DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY
ALPHA-EMITTING RADIOISOTOPE EXPECTED TO PLAY AN ESSENTIAL ROLE IN NEXT-GENERATION TARGETED CANCER THERAPIES
RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS
AGREEMENT PROVIDES RATIO ACCESS TO NUSANO-PRODUCED RADIOISOTOPES FOR ONCOLOGY DIAGNOSTICS AND THERAPEUTICS
NUSANO STABLE ISOTOPE PROGRAM ENRICHES GADOLINIUM-160 TO 99.2% PURITY
DOMESTIC STABLE ISOTOPE PROGRAM KEY TO STABILIZING SUPPLY CHAINS, ENABLING INNOVATION
CLARITY SIGNS HIGH-VOLUME COMMERCIAL-SCALE COPPER-64 SUPPLY AGREEMENT WITH NUSANO
CLARITY SIGNS HIGH-VOLUME COMMERCIAL-SCALE COPPER-64 SUPPLY AGREEMENT WITH NUSANO
NUSANO NAMES D. SCOTT HOLBROOK AS CHAIRMAN OF ITS BOARD
VALENCIA, Calif. – June 7, 2024 – Nusano, Inc., a physics company transforming the production of medical radioisotopes, today announced industry veteran D. Scott Holbrook as chairman of its board. Holbrook is the co-founder of Invivo Molecular Imaging, and currently serves as the general manager and chief strategy officer for Pharmalogic, a leading contract development […]
NUSANO OPENS RADIOCHEMISTRY LABORATORY TO ADVANCE ISOTOPE COMMERCIALIZATION AND CUSTOMER COLLABORATION
LU-177 SHIPMENTS EXPECTED TO BEGIN EARLY 2025, FOLLOWED BY AC-225
NUSANO NAMES ROHAN JAIN AS COMMERCIAL GENERAL MANAGER
Nusano Names Rohan Jain as Commercial General Manager.
NUSANO APPOINTS INDUSTRY EXPERT ALEXANDRE GIBIM AS CHIEF OPERATIONS OFFICER
EXECUTIVE WITH THREE DECADES OF SUCCESSFUL MULTINATIONAL OPERATIONS AND COMMERCIAL EXPERIENCE TO LEAD LAUNCH OF PROPRIETARY RADIOISOTOPE PRODUCTION PLATFORM
NUSANO TO PRESENT PRODUCTION CAPABILITIES TO EUROPEAN RADIOPHARMACEUTICALS WORKING GROUP
PROPRIETARY ION SOURCE AND BEAM TECHNOLOGY CAPABLE OF PRODUCING APPROXIMATELY 10 TIMES THE CURRENT GLOBAL SUPPLY OF ASTATINE-211
